Chugai Pharmaceutical Co. (CHGCY)
(Delayed Data from OTC)
$15.91 USD
+0.06 (0.38%)
Updated May 9, 2024 04:00 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
CHGCY 15.91 +0.06(0.38%)
Will CHGCY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CHGCY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CHGCY
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Upgraded to Buy: Here's Why
CHGCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Brookdale Senior Living (BKD) This Year?
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Is a Great Choice for 'Trend' Investors, Here's Why
Other News for CHGCY
Chugai Pharmaceutical Co., Ltd. 2024 Q1 - Results - Earnings Call Presentation
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q1 2024 Earnings Call Transcript
Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU
Argenx gains after setback to Roche/Chugai myasthenia gravis therapy
Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024